# Research Peptide FAQ — Pure Amino Peptides > Answers to common questions about GHK-Cu, BPC-157 and Ipamorelin: mechanisms, human evidence, safety, WADA status, regulatory standing. Cited literature summaries, no medical advice. What people actually want to know about these three research peptides — answered from the literature. ## What does a GHK-Cu peptide do? GHK-Cu is a copper-carrying tripeptide that acts as a signal for tissue-remodeling cells. In cell and animal studies it stimulates dermal fibroblasts to synthesize collagen, elastin, and structural proteoglycans; it enables copper-dependent cross-linking of those fibers via lysyl oxidase; and it shifts gene expression in repair, antioxidant, and DNA-repair directions [12][16]. In human topical studies it has stimulated collagen production in a higher proportion of treated subjects than vitamin C or retinoic acid at equivalent concentrations [14]. The copper in the complex is not decorative — it is the active cofactor, and the plain GHK tripeptide without copper is substantially less active [16]. ## What is GHK-Cu and how does it work? GHK-Cu is the tripeptide Gly-His-Lys chelated 1:1 to a copper(II) ion — three amino acids, one copper atom. It occurs endogenously in blood plasma and in the alpha-2(I) chain of type I collagen, where it is released when collagen is degraded, acting as a local repair signal. It works primarily by signaling fibroblasts and keratinocytes to rebuild the extracellular matrix, using copper as a cofactor for enzymatic cross-linking and antioxidant activity. Plasma GHK concentrations decline with age (roughly 200 ng/mL at 20, roughly 80 ng/mL at 60), which may contribute to aging skin's reduced repair capacity [14]. ## Is GHK-Cu peptide really anti-aging? In small controlled topical human studies, GHK-Cu has shown improvements in skin laxity, fine lines, wrinkle depth and density, and collagen production compared to placebo or other actives [14]. A 6-month RCT found statistically significant hair-count increases versus placebo with a GHK-containing formulation [13]. So there is actual controlled human data — more than exists for BPC-157 or Ipamorelin. The limitation is that studies are small and mostly topical; the broader gene-expression and systemic anti-aging claims rest on cell culture and database analyses, many from a single research group, and need more independent replication [11][12]. ## What is the difference between GHK and GHK-Cu? GHK is the plain tripeptide (Gly-His-Lys) without a metal ion. GHK-Cu is the same peptide chelated 1:1 to a copper(II) ion. The copper is required for most of the reported bioactivities: collagen stimulation, MMP-2 upregulation, lysyl-oxidase-mediated cross-linking, and antioxidant activity. In cell studies, GHK without copper did not reproduce key effects of GHK-Cu [16]. Products and studies using GHK rather than GHK-Cu may behave differently. Formulations should specify which form they contain. ## What does BPC-157 do in the body? In animal models, BPC-157 is reported to accelerate healing in tendons, gut lining, muscle, and nerve tissue. The mechanism most consistently supported by experiments is promoting new blood-vessel growth (angiogenesis) through upregulation and internalization of the VEGFR2 receptor, activating the downstream VEGFR2–Akt–eNOS pathway [4]. The peptide also modulates nitric oxide, serotonin, and dopamine systems in rodent work, and sensitizes the growth hormone receptor in tendon cells. In humans, the evidence base is extremely limited: a 2025 review identified only three small human pilot studies in the entire literature [2]. ## Is BPC-157 a growth hormone? No. BPC-157 is not a growth hormone and does not belong to the growth hormone axis. It is a 15-amino-acid gastric peptide whose primary experimental mechanism is angiogenic (new blood-vessel growth via VEGFR2) [4]. It has been reported in animal work to sensitize the growth hormone receptor in tendon fibroblasts, which may contribute to some tendon-repair effects, but it is not a GH-releasing peptide, a GH mimic, or a growth hormone secretagogue. That distinction matters for both regulatory and safety framing. ## Does BPC-157 work immediately? No controlled human data exists to answer this. In animal experiments, healing effects are observed over days to weeks rather than acutely. BPC-157 has a very short elimination half-life (under 30 minutes in rats and dogs) [3], so the intact peptide does not persist long — but its effects may outlast the peptide's presence if signaling pathways are activated. Community reports of tendon or joint changes describe improvement over one to three weeks of repeated use, not immediate effects, but these are anecdotal and not from controlled trials. There is no reliable human data on time-course for any outcome. ## Does BPC-157 damage the liver? There is no published evidence that BPC-157 damages the liver. In the only reported human IV safety study — two subjects — no measurable changes in hepatic biomarkers were detected [1]. In the formal pharmacokinetics study in rats and dogs, the peptide broke down rapidly into small amino-acid fragments via normal metabolism, with no reported hepatotoxic findings at the doses studied [3]. The 2025 narrative review of the literature does not identify liver toxicity as a documented concern but notes that the overall human safety dataset is very small and long-term data are absent [2]. Absence of evidence of liver damage in very limited studies is not the same as established liver safety. ## What is ipamorelin? Ipamorelin is a synthetic pentapeptide (five amino acids) that selectively activates the ghrelin receptor (GHS-R1a) on pituitary cells to trigger a pulse of growth hormone release. Its sequence (Aib-His-D-2-Nal-D-Phe-Lys-NH2) includes synthetic and D-amino acids that make it resistant to digestive enzymes. It has never been approved as a drug by any regulatory authority. The only published controlled human trial — for postoperative gut recovery — missed its primary endpoint [8]. It is prohibited in competitive sport under WADA S2. ## What does ipamorelin do for you? In research settings (not as a prescription or treatment), ipamorelin triggers a discrete pulse of growth hormone from the pituitary gland by activating the GHS-R1a receptor [9]. In rodent work this has been associated with increased bone-growth rates [10] and reduced chemotherapy-related weight loss [6]. In the only controlled human trial (postoperative ileus), the primary endpoint was not met [8]. People in research-use communities report benefits including deeper sleep, faster physical recovery, and a gradual shift toward leaner body composition — but these are anecdotal reports, not established clinical effects, and ipamorelin has no approved human indication. ## What is ipamorelin peptide? A synthetic pentapeptide GH-secretagogue — a peptide that makes the pituitary gland secrete growth hormone. Its full chemical name is Aib-His-D-2-Naphthylalanine-D-Phe-Lys-NH2, derived from GHRP-1 by removal of the central dipeptide. It was originally characterized by Novo Nordisk (under designation NNC 26-0161). It selectively binds GHS-R1a without meaningfully raising cortisol or prolactin, distinguishing it from older GHRPs. It is a research chemical, not a pharmaceutical product, and the FDA removed it from the 503A bulk-drug compounding list in 2024. ## What are the risks of ipamorelin? The most concrete known risks are WADA prohibition (S2, real sanctions risk for athletes) and absence of long-term human safety data [8][9]. Additional mechanism-based concerns include: a theoretical cancer risk from chronic GH/IGF-1 axis stimulation; unpredictable glycemic effects in people with insulin dysregulation (GH reduces insulin sensitivity and ipamorelin has direct insulinotropic activity on pancreatic islets in preclinical data); a class-level cardiovascular signal (a related GHS-R1a agonist produced cardiac muscle degeneration in 28-day rat dosing [7]); and orexigenic effects via hypothalamic ghrelin-receptor signaling. Supply purity from unregulated research-grade sources is unverified. --- A literature digest built around the chemistry — sequence, structure, mechanism, evidence — not the marketing.